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Restricted immune activation and internalisation of 
anti-idiotype complexes between drug and 
antidrug antibodies
Karin A van Schie,1 Simone Kruithof,1 pleuni ooijevaar-de Heer,1 ninotska I L derksen,1 
Fleur S van de Bovenkamp,1 Anno Saris,1 Gestur Vidarsson,2 Arthur E H Bentlage,2 
Wim Jiskoot,3 Stefan romeijn,3 roman I Koning,4 Erik Bos,4 Eva Maria Stork,5 
Carolien A M Koeleman,6 Manfred Wuhrer,6 Gertjan Wolbink,1,7 theo rispens1
ABstrAct
Objectives therapeutic antibodies can provoke an 
antidrug antibody (AdA) response, which can form 
soluble immune complexes with the drug in potentially 
high amounts. nevertheless, AdA-associated adverse 
events are usually rare, although with notable exceptions 
including infliximab. the immune activating effects and 
the eventual fate of these ’anti-idiotype’ complexes 
are poorly studied, hampering assessment of AdA-
associated risk of adverse events. We investigated the 
in vitro formation and biological activities of AdA-drug 
anti-idiotype immune complexes using patient-derived 
monoclonal anti-infliximab antibodies.
Methods Size distribution and conformation of AdA-
drug complexes were characterised by size-exclusion 
chromatography and electron microscopy. Internalisation 
of and immune activation by complexes of defined size 
was visualised with flow imaging, whole blood cell assay 
and C4b/c ELISA.
results Size and conformation of immune complexes 
depended on the concentrations and ratio of drug 
and AdA; large complexes (>6 IgGs) formed only with 
high AdA titres. Macrophages efficiently internalised 
tetrameric and bigger complexes in vitro, but not 
dimers. Corroborating these results, ex vivo analysis 
of patient sera demonstrated only dimeric complexes 
in circulation. no activation of immune cells by 
anti-idiotype complexes was observed, and only 
very large complexes activated complement. Unlike 
Fc-linked hexamers, anti-idiotype hexamers did not 
activate complement, demonstrating that besides size, 
conformation governs immune complex potential for 
triggering effector functions.
conclusions Anti-idiotype AdA-drug complexes 
generally have restricted immune activation capacity. 
Large, irregularly shaped complexes only form at high 
concentrations of both drug and AdA, as may be 
achieved during intravenous infusion of infliximab, 
explaining the rarity of serious AdA-associated adverse 
events.
IntrOductIOn
Millions of patients are nowadays treated with ther-
apeutic monoclonal antibodies that can be immu-
nogenic. Antidrug antibody (ADA) formation is a 
concern during the development of any biophar-
maceutical; the potential impact of immunogenicity 
is highlighted by the recent discontinuation of the 
PCSK9 inhibitor bococizumab, which was partly 
due to immunogenicity issues, despite promising 
clinical results.1 
For efficacy and safety reasons, immunogenicity 
assessment of therapeutic protein products, including 
monoclonal antibodies, is presently scrutinised by 
regulatory agencies such as the Food and Drug 
Administration. High ADA titres towards thera-
peutic proteins are associated with lower efficacy and 
reduced clinical response, although low amounts of 
ADA have little apparent consequences.2–6 Concerning 
safety, serious ADA-induced adverse events have been 
reported to various therapeutic proteins; erythropoi-
etin (EPO) likely being the most notorious example, 
with cases of ADA formation cross-reacting to endog-
enous EPO leading to pure red cell aplasia.7
For therapeutic antibodies, ADA formation may 
also positively correlate with incidence of adverse 
events. Particularly for infliximab and natalizumab, 
the risk of acute hypersensitivity reactions is 
increased in ADA-positive patients.8 9 However, for 
the majority of monoclonal antibodies, ADA posi-
tivity does not increase the occurrence of (severe) 
adverse events even in cases where ADA formation is 
clearly associated with diminished clinical response 
(eg, adalimumab2 10). A better understanding on the 
possible biological consequences of ADA would aid 
in assessment of immunogenicity-related risk and 
guidance of strategies for immunogenicity testing.
In ADA-positive patients, immune complexes 
between ADA and drug will form in vivo on treat-
ment. The contribution of these complexes to drug 
clearance and immune-mediated adverse events 
is not clear, but is expected to depend—among 
others—on size and shape. Therapeutic antibodies 
like adalimumab, infliximab or natalizumab predom-
inantly induce ADA responses towards the antigen 
binding site (or idiotype),9 11 12 thereby limiting 
the number of ADA molecules that may bind each 
Fab arm to just one.13 Consequently, therapeutic 
antibodies may be expected to bind to ADA—of 
which IgG is the major isotype14–16—in alternating 
fashion, forming circular or string-shaped immune 
complexes such as dimers, tetramers and hexamers 
(see lower panels of figure 1B).
Several studies investigated the size of these 
anti-idiotype complexes. Dimer-sized complexes 
were found in the majority of ADA-positive patients 
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treated with adalimumab 2 weeks after adalimumab administra-
tion.12 17 18 In cynomolgus monkeys treated with infliximab, 
dimers as well as complexes larger than 670 kDa (>4 antibodies) 
could be demonstrated.19 Infusion of (radiolabeled) infliximab 
into three ADA-positive patients led to dimer-sized complexes in 
two cases, without adverse events. However, complexes larger 
than 1000 kDa (>6 antibodies) were detected in a third patient 
that developed a severe infusion reaction, tentatively relating 
immune complex size to the adverse event.20
The differential effects of ADA on the occurrence of adverse 
events indicate that ADA-drug complexes are not invariably 
benign or harmful. However, for intravenously administered 
antibodies such as infliximab and natalizumab, high peak 
concentrations in serum of about 100–150 µg/mL are achieved, 
corresponding to roughly 1% of total serum IgG.21 22 If ADAs are 
present in serum, administered drug will quickly be bound upon 
infusion, leading to rapid formation of soluble IgG complexes, 
potentially reaching high concentrations in case of high ADA 
titres.
In this study, patient-derived human monoclonal anti-inflix-
imab antibodies are used to investigate the interplay between 
concentration and binding characteristics of ADA and drug, 
and the formation of different types of anti-idiotype immune 
complexes. Furthermore, the immune activating potential and 
clearance of ADA/drug complexes is investigated. The results of 
this study may advance the immunogenicity-related risk assess-
ment of (new) therapeutic antibodies.
MetHOds
See online supplementary materials and methods. 
results
A panel of patient-derived recombinant monoclonal anti-in-
fliximab antibodies was produced.23 All monoclonal antibodies 
competed with tumour necrosis factor (TNF) for binding inflix-
imab, as determined with a TNF competition assay (online 
supplementary table S1).24 This indicates that, similar to poly-
clonal anti-infliximab antibodies,24 they bind (close to) the 
drug’s idiotype.
In vitro, size of monoclonal and polyclonal complexes 
depends on concentration and ratio
We sought to investigate which factors influence the size of 
immune complexes. High-performance size-exclusion chro-
matography (HP-SEC) analysis of monoclonal anti-infliximab 
clones combined with infliximab in a 1:1 molar ratio demon-
strated different propensities of each anti-infliximab clone to 
form dimers, tetramers, hexamers and bigger complexes (online 
supplementary figure S1). Furthermore, for all ADA clones, the 
size of immune complexes depended highly on the concentra-
tions in which drug and ADA were mixed. At a 1:1 ratio, higher 
concentrations resulted in larger complexes, whereas dimers 
eventually became the predominant type of complex at very 
low concentrations, regardless of the clone (figure 1A). This 
Figure 1 Immune complex size is highly dependent on concentration. (A) Infliximab (IFX)-488 and different monoclonal anti-IFX antibodies were 
mixed at increasing concentrations in a 1:1 ratio. Afterwards, samples were diluted so that each sample contained an equal amount of labelled drug, 
and analysed by high-performance size-exclusion chromatography (HP-SEC). (B) Transmission electron microscopic (TEM) analysis of complexes 
between monoclonal anti-IFX 2.2 and IFX at 150 µg/mL, and schematic representation of their conformation. See also online supplementary figure S5. 
(C) A titration of polyclonal anti-IFX antibodies from a single patient mixed with an equimolar amount of IFX-488, analysed by HP-SEC. n=3 separate 
experiments. (D, E) Serum of anti-IFX-positive patients was mixed with an equimolar amount of IFX-488 and analysed using HP-SEC. (D) Example of 
the elution pattern of one patient serum. Percentage of dimers (red box) and complexes bigger than tetramers (blue box) was determined by dividing 
the area under the curve (AUC) of these complexes by the total AUC. (E) Percentage of specified complexes was correlated to the anti-IFX IgG titre for 
each patient (n=41). Spearman’s r for >tetramers: r=0.687, p<0.0001 and for dimers: r=−0.6676, p<0.0001.
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concentration dependency was corroborated by a similar titra-
tion of polyclonal anti-infliximab antibodies from a patient’s 
serum (figure 1C). Additionally, sera of 41 patients with anti-in-
fliximab levels ranging from 510 to 140 000 AU/mL (median 
1900 AU/mL) were mixed with an equimolar amount of inflix-
imab and the size distribution of complexes was analysed 
(figure 1D). A strong correlation was found between the titre 
and the percentage of complexes larger than tetramers, whereas 
an inverse correlation was found for dimers (figure 1E).
During infusion, ADA and drug are not immediately present 
in equimolar concentrations. We therefore tested the influence 
of different antibody/drug ratios. As expected,25 deviation of 
the 1:1 molar ratio caused a reduction of complex size (online 
supplementary figure S2A,B). A similar concentration and ratio 
dependency of immune complex size was also observed by 
combining monoclonal or polyclonal anti-adalimumab anti-
bodies with adalimumab (online supplementary figure S3A,B), 
indicating that these observations are a general phenomenon for 
anti-idiotype complex formation.
Since HP-SEC analysis could not accurately resolve complex 
sizes larger than hexamers, monoclonal antibody complexes 
were additionally analysed with asymmetric flow field flow frac-
tionation (AF4). Again, no distinct peaks of complexes larger 
than hexamers were observed (online supplementary figure S4), 
suggesting that they vary highly in their size and conformation. 
Transmission electron microscopic (TEM) analysis of these 
complexes supported this observation. Importantly, the confor-
mation of complexes as shown by TEM indicated Fab-Fab inter-
actions (figure 1B, online supplementary figure S5), in line with 
the anti-idiotypic nature of the interactions formed between 
ADA and drug.9 11 12 Thus, ADAs towards infliximab and adali-
mumab form circular or string-shaped anti-idiotype immune 
complexes, the size of which is influenced by both the concen-
tration and ratio of ADA and drug.
ex vivo, large immune complexes are absent in serum
Upon infusion of drug, ADA-positive patients will form immune 
complexes in vivo. We sought to determine which complexes 
are still present ex vivo just before the next infusion (ie, trough 
level). Trough sera of patients with varying anti-infliximab titres 
(range 12–70 000 AU/mL, median 40 AU/mL) were fractionated 
and tested for presence of anti-infliximab. No large complexes 
were detected in any of the sera (figure 2A and online supple-
mentary figure S6), although they could be observed in mono-
clonal antibody complexes subjected to the same fractionation 
procedures (figure 2B). However, small complexes resembling 
dimers were found in patients with low anti-infliximab titres.
Figure 2 Only small complexes and monomeric anti-infliximab antibodies are detected in patients at trough. Anti-infliximab antibody presence 
was determined with a drug-tolerant assay in (A) fractionated anti-infliximab positive sera and (B) fractionated monomeric anti-infliximab 2.1 
and complexes of anti-infliximab 2.4 and infliximab. Representative plots are shown for 3 out of 10 patients (A) and duplicate measurements of 
monoclonal complexes (B). Percentage binding is the sample measurement normalised to the total radioactively labelled input. IFX, infliximab. 
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large immune complexes are phagocytosed by macrophages
The discrepancy between the formation of large complexes in 
vitro and their absence ex vivo suggests that these complexes 
are preferentially and rapidly cleared in vivo. Since clearance 
is likely to occur via FcγRs, we first tested the binding of frac-
tionated complexes (dimers, tetramers, hexamers or larger 
complexes; figure 3A) to different FcγRs immobilised on a 
biosensor chip using surface plasmon resonance. As expected, 
dimeric complexes showed enhanced binding compared with 
monomeric IgG for all receptors tested, and larger complexes 
bound substantially stronger, largely due to a further reduction 
of the dissociation rate (figure 3B).
Next, we evaluated FcγR-mediated phagocytosis by mono-
cyte-derived macrophages in vitro. Of note, the exact immune 
complex size required for phagocytosis has not been identi-
fied so far. We generated three types of complexes (figure 4A): 
(A) virtually pure dimeric complexes using the anti-adalimumab 
clone 2.7, which has a strong preference for making dimers with 
adalimumab13; (B) pools of dimers and tetramers using anti-in-
fliximab 2.1; and (C) pools containing significant amounts of 
Figure 3 Binding to FcγRs increases with complex size. (A) Example of reanalysed fractions of immune complexes, done with high-performance 
size-exclusion chromatography (HP-SEC). (B) Representative sensograms of immune complexes binding to FcγRIIa, FcγRIIb, FcγRIIIa and FcγRIIIb 
on the chip. Receptor densities of shown sensograms are 10 nM for FcγRIIa and FcγRIIb, 3 nM for FcγRIIIa and 30 nM for FcγRIIIb, n=3 individual 
experiments. RU, response unit.
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large complexes (>tetramers) using anti-infliximab 2.4. Uptake 
of complexes by monocyte-derived macrophages polarised with 
granulocyte-macrophage colony stimulating factor (GM-CSF) 
(proinflammatory phenotype) or macrophage colony stimu-
lating factor (M-CSF) (anti-inflammatory phenotype) was anal-
ysed using flow imaging (figure 4B,C). Monomeric infliximab 
and adalimumab were not phagocytosed by GM-CSF macro-
phages and only slightly by M-CSF macrophages. Interestingly, 
also dimers (pool A) were not efficiently internalised. However, 
efficient internalisation was observed for tetramers (pool B) 
and bigger complexes (pool C; see also online supplementary 
figure S7 for time-lapse confocal imaging). Blocking of all FcγRs 
strongly inhibited binding and/or phagocytosis of infliximab and 
complexes (online supplementary figure S8A). Immune complex 
phagocytosis was predominantly mediated by FcγRI in GM-CSF 
and by FcγRII in M-CSF macrophages, likely due to differen-
tial FcγR expression on these cells (online supplementary figure 
S8B). Together, these results show that tetramers and larger 
complexes are phagocytosed in an FcγR-mediated fashion, but 
internalisation is much less efficient for dimers, consistent with 
the serological analysis shown in figure 2A.
Immune complexes do not activate immune cells
During intravenous administration of drug, complex formation 
occurs in the blood and the primary effects of antibody complexes 
are thus likely to happen within the blood circulation. We there-
fore investigated a possible proinflammatory effect of immune 
complexes in a whole blood cell activation assay, using inter-
leukin (IL)-6 production as read-out for activation. However, 
even very large complexes (anti-infliximab 2.4+infliximab 
made at 450 µg/mL, concentrations exceeding those achieved 
in patients) were not able to induce IL-6 production at 20 µg/
mL (data not shown) nor at 50 µg/mL (figure 5). In contrast, 
biotinylated beads opsonised with anti-biotin antibodies strongly 
induced IL-6 production. These results demonstrate that anti-id-
iotype antibodies have little proinflammatory capacity, possibly 
due to their size and/or conformation.
complement activation requires anti-idiotype complexes 
larger than hexamers
The lack of IL-6 production in whole blood cell cultures does not 
exclude the possibility that circulating immune complexes can 
activate the complement system. We therefore also tested pools 
Figure 4 Complexes larger than dimers are efficiently internalised by macrophages. (A) Example of the fluorescent complexes used. (B) 
Representative examples of three different intensity concentration ratio (ICR) values. The ICR calculates the logit-transformed ratio between the 
fluorescent intensity inside the cell and the fluorescent intensity of the entire cell. From left to right: bright-field image, green fluorescence of 
infliximab (IFX)-488 (in complex with anti-IFX), red fluorescence of secondary staining with anti-kappa antibodies (not used in analysis), mask (blue) 
to determine the inside of a cell. (C) Median ICR of monomers, dimers or pools of larger immune complexes, determined for GM-CSF (left) or M-CSF 
(right) macrophages after 75 min. n≥3 individual donors measured in duplicate. Statistical differences were calculated by one-way analysis of variance 
(ANOVA), with Sidak’s multiple comparison test; * and ** denote a statistical significance of p≤0.05 and p≤0.01, respectively. ADL, adalimumab; GM-
CSF, granulocyte-macrophage colony stimulating factor; M-CSF, macrophage colony stimulating factor; ns, not significant. 
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of small and large anti-idiotype complexes for their capacity 
to activate complement. Pools of (predominantly) dimers and 
tetramers (anti-infliximab 2.1+infliximab) did not activate 
complement (figure 6A). However, pools containing—in addi-
tion to tetramers—hexamers and a variety of bigger complexes 
(anti-infliximab 2.4+infliximab) gave significant activation of 
the complement system. As expected, strong complement activa-
tion was also observed for the antibody-coated beads used in the 
whole blood cell assay (online supplementary figure S9).
To more specifically pinpoint the size of anti-idiotype 
complexes required for complement activation, we fraction-
ated the pools of complexes to obtain samples with only dimers, 
tetramers, hexamers or complexes larger than hexamers (high 
molecular weight, HMW), and tested their individual activa-
tion capacity. No activation was seen for hexamers and smaller 
complexes, but a (non-significant) trend towards complement 
activation was found for the complexes with the highest molec-
ular weight, suggesting that anti-idiotype complexes should be 
(substantially) larger than hexamers to activate complement 
(figure 6B). To exclude the possibility that abnormal Fc glyco-
sylation of recombinant antibodies reduced the complement acti-
vating potential, Fc glycopeptides of all antibodies were analysed 
(online supplementary figure S10). However, the slight differ-
ences that were found compared with IVIg could not explain the 
lack of complement activation.26
Recently it was shown that RGY-mutant antibodies, which 
have a triple-mutated Fc, form fluid phase Fc-Fc interacting 
hexamers mimicking similar hexameric structures formed by 
IgG on opsonising a cellular target. These hexameric complexes 
potently activate the complement system via C1q.27 28 Since our 
anti-idiotype hexamers do not activate complement, we inves-
tigated the potency of Fc-Fc interacting hexamers of IgG1-
b12-RGY in our system, and indeed found strong complement 
activation (figure 6B). The contrasting results between anti-id-
iotype and Fc-Fc interacting hexamers strongly suggest that the 
conformation of immune complexes is crucial for complement 
activation.
dIscussIOn
Immunogenicity of therapeutic monoclonal antibodies is a 
recognised problem, and the relation between ADA forma-
tion and reduced efficacy has been demonstrated in numerous 
studies. Nevertheless, few studies addressed the pathophysiolog-
ical effects of these immune responses, and therefore the impact 
of ADA on safety remains largely unknown. In this study, we 
investigated the factors influencing ADA-drug complex forma-
tion and determined the biological activities of these complexes. 
Data presented in this paper show for the first time that anti-idio-
type complexes with distinct conformations are formed between 
drug and ADA, and that the majority of these complexes have 
a restricted capacity to cause immune activation. This would 
imply that for many therapeutic antibodies an ADA response will 
not ordinarily result in adverse events, given that such responses 
tend to predominantly consist of anti-idiotype antibodies.9 11 12
Antibody concentration and ADA/drug ratio were found to 
greatly influence complex size in patient sera. Although large 
complexes were formed in vitro, these were not detected ex 
vivo in trough serum samples of infliximab-treated patients. The 
rapid phagocytosis of tetramers and larger complexes by macro-
phages suggests that these complexes are cleared in vivo. On the 
other hand, our study shows that dimers can persist in circula-
tion for prolonged times, in line with previous observations from 
our group for adalimumab.12 Their impaired internalisation by 
macrophages suggests that dimers are too small to be efficiently 
cleared.
Figure 5 Large immune complexes do not have a proinflammatory effect on whole blood cell (WBC) cultures. Interleukin (IL)-6 production by 
WBC cultures was determined after addition of monomeric antibodies or large immune complexes (infliximab+anti-infliximab 2.4 mixed at 150 
and 450 µg/mL of both antibodies). All samples were tested at 50 µg/mL of each antibody in 10-fold diluted blood, giving a supratherapeutic 
concentration. Anti-biotin-coated beads (100 or 10 µg/mL) and lipopolysaccharide (LPS) were used as positive control, WBC medium was used as 
negative control. Statistical differences were calculated by one-way analysis of variance (ANOVA), and further compared with the negative control by 
using Dunnett’s multiple comparison test; *** denotes a statistical significance of p≤0.001. Unless indicated, no significant differences were found. 
Cut-off (dotted line) was set at the mean plus twice the SD of the negative control. IFX, infliximab. 
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The valency required for FcγR-mediated inhibition of phago-
cytosis was also investigated by Ortiz et al,29 showing that 
Fc trimers were not internalised by FcγR expressing THP-1 cells, 
in contrast to Fc pentamers. Our study now suggests that at least 
four Fc moieties are required for efficient internalisation.
Contrary to their findings, our results suggest a clear depen-
dency on immune complex conformation, in addition to 
mere Fc-tail valency, as an important factor determining the 
immune-activating properties of an immune complex (see 
below).
We only observed complement activation for the very large—
irregularly shaped—anti-idiotype complexes, whereas hexamers 
and smaller complexes did not activate complement. It has been 
known for decades that the classical pathway of the comple-
ment cascade is activated by multimerisation of antibodies on a 
surface or in fluid phase, but the detailed molecular mechanisms 
are only now being fully elucidated. In older studies, chemically 
cross-linked IgG forming dimers, trimers and tetramers were 
found to increasingly activate complement.30 31 However, it 
is unclear to which extent these artificial complexes resemble 
complexes formed during an actual immune response. More 
recently, six Fc-Fc interacting antibodies were found to be the 
optimal amount for C1q docking and activation with the Fc tails 
pointing inward forming a hexameric structure also sometimes 
observed in crystal structures of human IgG.27 28 This provides 
a platform for C1q to dock onto. Interestingly, the anti-idiotype 
complexes generated by ADA and drug have a completely 
opposite conformation compared with the Fc-Fc interacting 
hexamers: since ADA and drug interact through their Fab arms, 
the Fc tails will point outward. Therefore, ADA-drug-induced 
hexamers, but also dimers and tetramers, do not form a struc-
turally optimal C1q platform like Fc-Fc interacting hexamers, 
probably explaining their lack of complement activity. Upon 
generation of larger complexes than hexamers the conforma-
tion is likely to become more disorganised (also suggested by 
our AF4 and TEM results), allowing some Fc tails to come into 
closer contact, thereby serving as a more optimal C1q docking 
platform. Large disorganised complexes may therefore acti-
vate complement to a certain extent, but this is expected to be 
restricted to situations of high ADA titres.
For infliximab8 21 32 and natalizumab,9 33 clinical studies show 
that ADA positivity and high ADA titres34 are associated with 
infusion reactions. These encompass all symptoms that occur 
during or shortly after infusion, and may be mild (eg, dizziness, 
nausea), moderate (eg, chest tightening, urticaria) or severe (eg, 
significant hyper/hypotension, stridor).35 While these symptoms 
resemble those of an IgE-mediated type I hypersensitivity, the 
vast majority of patients experiencing an infliximab-induced 
infusion reaction are negative for IgE anti-infliximab,23 36 37 
and no elevated tryptase levels are found in infusion reaction 
positive+ patients.35 38 By contrast, our study provides a mech-
anistic link between high IgG ADA titres and the formation of 
Figure 6 Anti-idiotype complexes larger than hexamers are required for activation of the complement system. (A) Representative elution patterns of 
complexes between infliximab with either anti-infliximab 2.1 or 2.4 made at 150 and 450 µg/mL of both antibodies, respectively. Bottom: complexes 
(final antibody concentration 100 µg/mL in serum) were tested in the C4b/c ELISA. n=5 serum donors, each dot represents the mean of two to five 
experiments per donor. Significant differences were calculated by one-way analysis of variance (ANOVA), with Sidak’s multiple comparison test; 
*** denotes a statistical significance of p≤0.001. (B) Representative elution patterns of immune complexes consisting of infliximab with either 
anti-infliximab 2.4 (upper left) or 2.1 (upper right). Selected fractions are shown in coloured boxes. Bottom: all fractions and IgG1-b12-RGY were 
separately tested in the C4b/c ELISA (final antibody concentration 15 µg/mL in serum). n=5 serum donors, representative of ≥4 individual experiments. 
Buffer was used as negative control and aggregated human gammaglobulin (AHG) as positive control. Dotted line is twice the mean buffer value. 
Similar colours in top and bottom figures show corresponding samples. HMW, high molecular weight; IFX, infliximab; ns, not significant. 
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large, irregularly shaped immune complexes that—under privi-
leged circumstances—can activate complement. Our results thus 
suggest that, instead of an IgE-mediated response, infusion reac-
tions may represent type III hypersensitivity.
Anti-infliximab/adalimumab antibodies are largely (>90%)24 
anti-idiotype antibodies. We here demonstrate that ADA-drug 
complexes formed with anti-idiotypic antibodies have restricted 
immune activating capacities. It however remains unknown to 
what extent the small fraction of non-anti-idiotypic ADA influ-
ences this restricted activation.
During infusion of drug in ADA-positive patients, drug is 
effectively titrated to ADA in vivo. The concentration of ADA at 
the site of infusion and the infusion rate will influence the type 
of complexes that are formed. At first, ADA will theoretically be 
in excess, probably resulting predominantly in smaller, trimeric 
complexes (ie, one drug and two ADA molecules). However, 
when a ratio approaching equimolarity is reached, larger 
complexes will be formed. The concentration of both antibodies 
at equimolarity will determine the size of the complexes and 
their (clinical) effects. The current management to ameliorate 
infusion reactions by reducing the infusion speed may impact 
the effective (local) peak drug concentrations, thereby reducing 
the risk of a severe infusion reaction. In contrast to intravenous 
administered therapeutics, subcutaneous administration leads to 
a local high concentration of drug, thereby taking the ADA-drug 
ratio far from equimolarity. Although little is known about their 
actual in vivo formation, the formed complexes are expected to 
be small, and are likely even more slowly distributed than mono-
meric drug molecules.39 These properties may prevent systemic 
reactions in a dual manner.
As shown in this study, immune complexes larger than dimers 
are efficiently taken up by macrophages in vitro. ADA formation 
thus may reduce the drug concentration in vivo,19 but this inher-
ently also reduces the ADA concentration. This complicates the 
assessment of immunogenicity, since one cannot measure ADA 
that is already cleared. So, immune complex clearance can lead 
to underestimation of the immunogenicity of antibody thera-
peutics. In any case, these results warrant caution against inter-
pretation of quantitative aspects of ADA formation, and show 
that even multitiered testing approaches may not reveal the full 
extent of an ADA response.
Taken together, immune complex formation between ADA 
and drug results in large immune complexes when the concentra-
tion of both antibodies is high, but the anti-idiotype conforma-
tion limits the formation of complexes capable of complement 
or immune cell activation. Very large immune complexes may be 
formed and adverse events may occur in those cases where ADA 
levels are very high and the administered amounts of drug as 
well (upward of ca 50–100 µg/mL), typically only during intra-
venous administration.
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